The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation
- 1 January 2008
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 158 (1) , 77-83
Abstract
Objective: This retrospective study describes the role of serum thyroglobulin (Tg) in relation to tumor characteristics in the prediction of persistent/recurrent disease in patients with differentiated thyroid cancer (DTC) with negative Tg at the time of ablation.Design: Between 1989 and 2006, 94 out of 346 (27%) patients with DTC had undetectable Tg at the time of131I ablation and were included in this evaluation. The group of 94 patients consisted of 15 males and 79 females in the age range of 16–89 years with a median follow-up of 8 years (range 1–17). All medical records and follow-up parameters of the 94 patients were evaluated for the occurrence of persistent/recurrent disease. In patients with persistent/recurrent disease hematoxylin-eosin-stained slides of the primary tumors and/or metastatic lesions were also reviewed for histological features including immunostains for Tg.Results: During follow-up, 8 out of 94 (8.5%) patients showed persistent/recurrent disease: in the course of the disease two patients showed Tg positivity, three showed Tg antibody (TgAb) positivity, and the other three showed persistently undetectable Tg and TgAb. Patients who developed Tg and/or TgAb positivity during follow-up had a significantly shorter disease-free survival period when compared with patients with persistently undetectable Tg and TgAb (P<0.006). Histological features were not able to predict the recurrent status.Conclusions: Follow-up of Tg and TgAb in patients with initially negative Tg and TgAb is useful since a number of patients had shown detectable Tg or TgAb during follow-up indicative for persistent/recurrent disease. Tg and TgAb negativity at the time of ablation is not a predictive determinant for future recurrent status.Keywords
This publication has 17 references indexed in Scilit:
- Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancerClinical Endocrinology, 2007
- Clinical Utility of an Automated Immunochemiluminometric Thyroglobulin Assay in Differentiated Thyroid CarcinomaClinical Chemistry, 2006
- Life expectancy in differentiated thyroid cancer: a novel approach to survival analysisEndocrine-Related Cancer, 2005
- Neck recurrence from thyroid carcinoma: serum thyroglobulin and high‐dose total body scan are not reliable criteria for cure after radioiodine treatmentClinical Endocrinology, 2005
- Relationship Between Tumor Burden and Serum Thyroglobulin Level in Patients with Papillary and Follicular Thyroid CarcinomaThyroid®, 2002
- Recurrent Differentiated Thyroid Cancer without Elevation of Serum ThyroglobulinThyroid®, 2000
- Serum Thyroglobulin Autoantibodies: Prevalence, Influence on Serum Thyroglobulin Measurement, and Prognostic Significance in Patients with Differentiated Thyroid CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 1998
- Papillary and Follicular Thyroid CarcinomaNew England Journal of Medicine, 1998
- Thyroglobulin may be undetectable in the serum of patients with metastatic disease secondary to differentiated thyroid carcinoma. Follow-up of differentiated thyroid carcinomaCancer, 1984
- Control of Thyroglobulin Synthesis and SecretionNew England Journal of Medicine, 1979